The magnitude of early response to methotrexate therapy predicts long-term outcome of patients with juvenile idiopathic arthritis

Annals of the Rheumatic Diseases

Volumn 67, Issue 3, 2008, Pages 370-374

  Bartoli, M ^a   Taro M ^b   Magni Manzoni, S ^a   Pistorio, A ^b   Traverso, F ^b   Viola, S ^b   Magnani, A ^b   Gasparini, C ^a   Martini, A ^b   Ravelli, A ^b  

^a FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

^b G GASLINI INSTITUTE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; METHOTREXATE; PREDNISONE;

ARTICLE; CONTROLLED STUDY; FEMALE; FOLLOW UP; HUMAN; JUVENILE RHEUMATOID ARTHRITIS; MAJOR CLINICAL STUDY; MALE; PRESCHOOL CHILD; PRIORITY JOURNAL; TREATMENT OUTCOME; TREATMENT RESPONSE; VISUAL ANALOG SCALE;

ANTIRHEUMATIC AGENTS; ARTHRITIS, JUVENILE RHEUMATOID; CHILD; CHILD, PRESCHOOL; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; METHOTREXATE; PROGNOSIS; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; TIME FACTORS; TREATMENT OUTCOME;

EID: 39549121704     PISSN: 00034967     EISSN: None     Source Type: Journal    
DOI: 10.1136/ard.2007.073445     Document Type: Article

References (32)

1. Giannini EH, Ruperto N, Ravelli A, Lovell DJ, Felson DT, Martini A. Preliminary definition of improvement in juvenile arthritis. Arthritis Rheum 1997;40:1202-9.
2. Giannini EH, Brewer EJ, Kuzmina N, Shaikov A, Maximov A, Vorontsov I, et al. Methotrexate in resistant juvenile rheumatoid arthritis. Results of the USA-USSR double-blind, placebo-controlled trial. The Pediatric Rheumatology Collaborative Study Group and The Cooperative Children's Study Group. N Engl J Med 1992;326:1043-9.
3. Ruperto N,. Murray KJ, Gerloni V, Wulffraat N, de Oliveira SK, Falcini F, et al. A randomized trial of parenteral methotrexate in intermediate versus higher doses in children with juvenile idiopathic arthritis who failed standard dose. Arthritis Rheum 2004;50:2191-201.
4. Lovell DJ, Giannini EH, Reiff A, Cawkwell GD, Silverman ED, Nocton JJ, et al. Etanercept in children with polyarticular juvenile rheumatoid arthritis. N Engl J Med 2000;342:763-9.
5. Ruperto N, Lovell DJ, Woo P, Petty RE, Cuttica R, Wilkinson N, et al. A randomized trial of infliximab plus methotrexate for the treatment of polyarticular course juvenile rheumatoid arthritis. Arthritis Rheum 2007;56:3096-106.
6. Ruperto N, Lovell DJ, Goodman S, Reiff A, Jung L, Nemcova D, et al. 48-week data from the study of adalimumab in children with juvenile rheumatoid arthritis (JRA) [Abstract]. Ann Rheum Dis 2006;65(Suppl 11):56.
7. Ruperto N, Lovell DJ, Prieur AM, Paz E, Rubio Perez NE, Silva CA, et al. Efficacy and safety of abatacept in children and adolescents with active juvenile idiopathic arthritis (JIA) [Abstract]. Ann Rheum Dis 2006;65(Suppl 11):248.
8. Felson DT, Anderson JJ, Boers M, Bombardier C, Furst D, Goldsmith C, et al. Preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum 1995;38:727-35.
9. Felson DT. Whither the ACR20? J Rheumatol 2004;31:835-7.
10. Pincus T, Sokka T, Kavanaugh A. Relative versus absolute goals of therapies for RA: ACR 20 or ACR 50 responses versus target values for "near remission" of DAS or single measures. Clin Exp Rheumatol 2004;22(Suppl 35):S50-6.
11. Pincus T, Sokka T. Partial control of Core Data Set measures and Disease Activity Score (DAS) measures of inflammation does not prevent long-term damage: evidence from longitudinal observations over 5-20 years. Clin Exp Rheumatol 2002;20(Suppl 27):S42-8.
12. Fransen J, van Riel PLCM. DAS remission cutpoints. Clin Exp Rheumatol 2006;24(Suppl 43):S29-S32.
13. Ranganath VK, Khanna D, Paulus HE. ACR remission criteria and response criteria. Clin Exp Rheumatol 2006;24(Suppl 43):S14-S21.
14. Felson DT, Anderson JJ, Lange MLM, Wells G, LaValley MP. Should improvement in rheumatoid arthritis clinical trials be defined as fifty percent or seventy percent improvement in core set measures, rather than twenty percent? Arthritis Rheum 1998;41:1564-70.
15. Chung CP, Thompson JL, Koch GG, Amara I, Strand V, Pincus T. Are American College of Rheumatology 50% response criteria superior to 20% criteria in distinguishing active aggressive treatment in rheumatoid arthritis clinical trials reported since 1997? A meta-analysis of discriminant capacities. Ann Rheum Dis 2006;65:1602-7.
16. Fransen J, van Riel PLCM. Are better endpoints and better design of clinical trials needed? Best Pract Res Clin Rheumatol 2004;18:97-109.
17. Verstappen SMM, van Albada-Kuipers, GA, Bijlsma JWJ, Blaauw AAM, Schenk Y, et al. A good response to early DMARD treatment of patients with rheumatoid arthritis in the first year predicts remission during follow up. Ann Rheum Dis 2005;64:38-43.
18. Petty RE, Southwood TR, Manners P, Baum J, Glass DN, Goldenberg J, et al. International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton 2001. J Rheumatol 2004;31:390-2.
19. Ravelli A, Viola S, Ruperto N, Corsi B, Ballardini G, Martini A. Correlation between conventional disease activity measures in juvenile chronic arthritis. Ann Rheum Dis 1997;56:197-200.
20. Ruperto N, Ravelli A, Pistorio A, Malattia C, Viola S, Cavuto S, et al. The Italian version of the Childhood Health Assessment Questionnaire (CHAQ) and the Child Health Questionnaire (CHQ). Clin Exp Rheumatol 2001;19(Suppl 23):S91-5.
21. Ravelli A, Viola S, Ramenghi B, Di Fuccia G, Ruperto N, Zonta L, Martini A. Evaluation of response to methotrexate by a functional index in juvenile chronic arthritis. Clin Rheumatol 1995;14:322-6.
22. Howe S, Levinson J, Shear E, Hartner S, McGirr G, Schulte M, et al. Development of a disability measurement tool for juvenile rheumatoid arthritis. The Juvenile Arthritis Functional Assessment Report for children and their parents. Arthritis Rheum 1991;34:873-80.
23. Poznanski AK, Hernandez RJ, Guire KE, Bereza U, Garn SM. Carpal length in children - a useful measurement in the diagnosis of rheumatoid arthritis and some congenital malformation syndromes. Radiology 1978;129:661-8.
24. Magni-Manzoni S, Rossi F, Pistorio A, Temporini F, Viola S, Beluffi G, et al. Prognostic factors for radiographic progression, radiographic damage, and disability in juvenile idiopathic arthritis. Arthritis Rheum 2003;48:3509-17.
25. Wallace CA, Ruperto N, Giannini EH. Preliminary criteria for clinical remission for select categories of juvenile idiopathic arthritis. J Rheumatol 2004;31:2290-4.
26. Dougados M. It's good to feel better but it's better to feel good. J Rheumatol 2005;32:1-2.
27. Irvine S, Capell HC. Great expectations of modern RA treatment. Ann Rheum Dis 2005;64:1249-51.
28. FDA. Rheumatology Working Group of the Medical Policy Coordinating Committee (MPCC) of the Center for Drug Evaluation and Research (CDER), the Center for Biologics Evaluation and Research (CBER), and the Center for Devices and Radiological Health (CDRH). Guidance for industry: clinical development programs for drugs, devices, and biological products for the treatment of rheumatoid arthritis (RA), 1999. http://www.fda.gov/cder/guidance/1208fnl.pdf (accessed 21 February 2007).
29. Fries JF, Williams CA, Morfeld D, Singh G, Sibley J. Reduction of long-term disability in patients with rheumatoid arthritis by disease-modifying antirheumatic drug-based treatment strategies. Arthritis Rheum 1996;39:616-22.
30. Grigor C, Capell H, Stirling A, McMahon ad, Lock P, Vallance R, et al. Effect of a treatment strategy of tight control of rheumatoid arthritis (the TICORA study): a single-blind randomized controlled trial. Lancet 2004;364:263-9.
31. Ravelli A, Martini A. Methotrexate in juvenile idiopathic arthritis: answers and questions. J Rheumatol 2000;27:1830-3.
32. Ravelli A, Martini A. Juvenile idiopathic arthritis. Lancet 2007;369:767-78.